A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Completed · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumors
In brief
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
Key facts
- Study ID
- NCT03861793
- Run by
- Mural Oncology, Inc
- People needed
- 116
- Starts
- 2019-02-26
- Expected to finish
- 2023-03-01
- Last updated by the study team
- 2024-03-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- For Phase I the subject has histological or cytological evidence of a solid tumor. For Phase II the subject must have 1 of the specified adult solid tumor types: gastric, ovarian, lung, head and neck.
- Subject must have at least one target lesion based on RECIST
- Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1
- Subjects must have adequate liver function
- Subjects must have adequate kidney function
- Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery
- Subjects who have received radiation therapy must wait at least 4 weeks after their last radiation treatment before enrollment into the study
- Females of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and on Day 1 before the first dose is administered
- Subject will agree to follow contraceptive requirements defined in the protocol
- Additional criteria may apply
You may not qualify if…
- Subject is currently pregnant, planning to become pregnant, or breastfeeding
- Subjects with an active infection or with a fever ≥ 38.5°C within 3 days of the first scheduled day of dosing for Cycle 1
- Subjects with active or symptomatic central nervous system metastases are excluded. Subjects with central nervous system metastases are eligible for the study if the metastases have been treated by surgery and/or radiation therapy, the subject is off corticosteroids for at least 2 weeks, and the subject is neurologically stable
- Subjects with known hypersensitivity to any components of ALKS 4230 or to pembrolizumab or any of its excipients
- Subjects who require pharmacologic doses of systemic corticosteroids are excluded; replacement doses, topical, ophthalmologic, and inhalational steroids are permitted
- Subjects who developed autoimmune disorders while on prior immunotherapy, including pneumonitis, nephritis, and/or neuropathy
- Subjects with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the subjects to cooperate and participate in the study
- The subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B or C, or active tuberculosis, or has a known history of tuberculosis
- Additional criteria may apply
Where it is running
- Mural Oncology Investigational Site — Los Angeles, California, United States
- Mural Oncology Investigational Site — Los Angeles, California, United States
- Mural Oncology Investigational Site — Washington D.C., District of Columbia, United States
- Mural Oncology Investigational Site — Atlanta, Georgia, United States
- Mural Oncology Investigational Site — Chicago, Illinois, United States
- Mural Oncology Investigational Site — Bethesda, Maryland, United States
- Mural Oncology Investigational Site — Detroit, Michigan, United States
- Mural Oncology Investigational Site — Saint Paul, Minnesota, United States
- Mural Oncology Investigational Site — Morristown, New Jersey, United States
- Mural Oncology Investigational Site — Buffalo, New York, United States
- Mural Oncology Investigational Site — Huntersville, North Carolina, United States
- Mural Oncology Investigational Site — Cincinnati, Ohio, United States
- Mural Oncology Investigational Site — Philadelphia, Pennsylvania, United States
- Mural Oncology Investigational Site — Charleston, South Carolina, United States
- Mural Oncology Investigational Site — Houston, Texas, United States
- Mural Oncology Investigational Site — Salt Lake City, Utah, United States
- Mural Oncology Investigational Site — Milwaukee, Wisconsin, United States
- Mural Oncology Investigational Site — Edmonton, Alberta, Canada
- Mural Oncology Investigational Site — Hamilton, Ontario, Canada
- Mural Oncology Investigational Sites — Montreal, Quebec, Canada
- Mural Oncology Investigational Site — Montreal, Quebec, Canada
- Mural Oncology Investigational Site — Montreal, Quebec, Canada
- Mural Oncology Investigational Site — Québec, Quebec, Canada
- Mural Oncology Investigational Site — Rotterdam, Netherlands
- Mural Oncology Investigational Site — Utrecht, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.